Two blockbuster potential stroke/DVT drugs report good results at ESC Congress: Bristol-Myers/Pfizer's apixaban and Bayer/J&J's rivaroxaban

1 September 2010

Presentations as the European Cardiology Society meeting taking place in Stockholm, Sweden, showed encouraging late-stage results for two drug candidates that could replace warfarin and aspirin in the prevention of blood clots and stroke and vie for a stake in a global market sector estimated to be worth around $20 billion a year.

Date were revealed on US drug major Bristol-Myers Squibb's (NYSE: BMY) and behemoth Pfizer's (NYSE: PFE) apixaban - showing the drug reduced the rate of stroke by 52% compared with aspirin - and Germany's Bayer (BAY; DE) and USA-based partner Johnson & Johnson's (NYSE: JNJ) Xarelto (rivaroxaban) ' which showed similar efficacy and safety compared to standard therapy, Sanofi-Aventis' Lovenox (enoxaparin) plus warfarin, for the prevention of recurrent venous thromboembolism (VTE) in patients with deep vein thrombosis (DVT).

The Phase III EINSTEIN-DVT clinical trial of the oral anticoagulant rivaroxaban demonstrated non-inferiority compared to the standard of care for the prevention of recurrent venous thromboembolism (VTE) in patients with acute symptomatic deep vein thrombosis (DVT), with a comparable safety profile.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical